The ultimate goal in the treatment of neonatal Rh-disease is prevention of hyperbilirubinemia and bilirubin encephalopathy syndrome. Therapeutic approaches as exchange transfusion, phototherapy, reduction of enterohepatic circulation and enzyme induction are discussed on the basis of bilirubin metabolism. The impact of endogenous and exogenous factors upon bilirubin-albumin binding is emphasized in more detail. Two main theories for the pathogenesis of bilirubin encephalopathy syndrome are currently under discussion: the cytotoxicity of the free, unbound bilirubin fraction or the transient opening of the blood brain barrier secondary to asphyxia, acidosis and hyperosmolarity.
Download full-text PDF |
Source |
---|
Clin Transplant
February 2025
Division of Transplantation Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland, USA.
Introduction: Hepatic epithelioid hemangioendothelioma (HEH) is a rare indication of liver transplant with limited evidence.
Methods: Adult recipients undergoing first-time liver-only transplant from 2002 to 2021 in the United States were identified using the UNOS/OPTN database. We compared post-transplant outcomes of recipients receiving liver transplant for HEH versus other diagnoses.
Brain Res
January 2025
Neuropharmacology Division, Department of Pharmacology, ISF College of Pharmacy, Moga 142001, Punjab, India. Electronic address:
Neurodegenerative disorders are characterized by a progressive loss of neurons, causing substantial deficits in motor and cognitive functioning. Bilirubin is a yellow by-product of heme, existing in two primary isoforms namely unconjugated and conjugated, while initially produced unconjugated isomer is lipophilic and cytotoxic in nature. At physiological levels, bilirubin has an important role in brain function by acting as a powerful antioxidant, preventing brain tissues from oxidative damage by eliminating reactive oxygen species (ROS).
View Article and Find Full Text PDFAim And Background: This study aimed to evaluate the efficacy of silymarin in improving liver function and reducing liver stiffness in chronic liver disease (CLD) patients. Silymarin, a hepatoprotective agent, has shown potential benefits in non-alcoholic fatty liver disease (NAFLD) and liver fibrosis, but evidence in CLD with varied etiologies remains limited. This study addresses the gap by assessing its impact across diverse etiological subgroups.
View Article and Find Full Text PDFTunis Med
January 2025
Department of Gastroenterology, Charles Nicolle Hospital, Faculty of Medicine of Tunis, University of Tunis-Manar, Tunis, Tunisia.
Introduction: Acute decompensation represents a remarkable event in cirrhotic patients, particularly if it is complicated by Acute-on-Chronic Liver Failure (ACLF). Epidemiological data of ACLF are limited.
Aim: To determine the prevalence and predictive factors of ACLF in patients hospitalized for decompensated cirrhosis.
Diagnostics (Basel)
December 2024
Department of Internal Medicine and Gastroenterology, Carol Davila University of Medicine, 020021 Bucharest, Romania.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!